Katsuhide Maeda

Katsuhide Maeda

Auto-generated profile, based on publicly available information

Katsuhide Maeda

University of Pennsylvania

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
JSJoshua Saef
Joshua Saef
RMRobert Montgomery
Robert Montgomery
ACAri Cedars
Ari Cedars
WTW.H. Wilson Tang
W.H. Wilson Tang
JRJoseph W. Rossano
Joseph W. Rossano
SVSumeet S. Vaikunth
Sumeet S. Vaikunth
Adults with congenital heart disease (ACHD) patients are one of the fastest growing populations in cardiology, and heart failure (HF) is the most common cause of morbidity and mortality amongst them. The need for advanced HF therapies in ACHD patients stands to grow substantially. The anatomic considerations for placing durable mechanical circulatory support (MCS) devices in ACHD patients often require specialized approaches. Despite this, increasing evidence suggests that durable MCS can be implanted safely with favorable outcomes in ACHD patients. Expansion of MCS use in ACHD patients is imperative to improve their clinical outcomes. Knowledge of ACHD-specific anatomic and physiologic considerations is crucial to HF programs’ success as they work to provide care to this growing population.

27 December 2022 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Open access
WWWai Wong
Wai Wong
BJBrandy Johnson
Brandy Johnson
PCPi Chun Cheng
Pi Chun Cheng
MJMaureen B. Josephson
Maureen B. Josephson
KMKatsuhide Maeda
Katsuhide Maeda
AHAdam S. Himebauch
Adam S. Himebauch
Severe primary graft dysfunction (PGD) is associated with the development of bronchiolitis obliterans syndrome (BOS), the most common form of chronic lung allograft dysfunction (CLAD), in adults. However, PGD associations with long-term outcomes following pediatric lung transplantation are unknown. We hypothesized that PGD grade 3 (PGD 3) at 48- or 72-hours would be associated with shorter CLAD-free survival following pediatric lung transplantation. This was a single center retrospective cohort study of patients ≤ 21 years of age who underwent bilateral lung transplantation between 2005 and 2019 with ≥ 1 year of follow-up. PGD and CLAD were defined by published criteria. We evaluated the association of PGD 3 at 48- or 72-hours with CLAD-free survival by using time-to-event analyses. Fifty-one patients were included (median age 12.7 years; 51% female). The most common transplant indications were cystic fibrosis (29%) and pulmonary hypertension (20%). Seventeen patients (33%) had PGD 3 at either 48- or 72-hours. In unadjusted analysis, PGD 3 was associated with an increased risk of CLAD or mortality (HR 2.10, 95% CI 1.01-4.37, p=0.047). This association remained when adjusting individually for multiple potential confounders. There was evidence of effect modification by sex (interaction p = 0.055) with the association of PGD 3 and shorter CLAD-free survival driven predominantly by males (HR 4.73, 95% CI 1.44-15.6) rather than females (HR 1.23, 95% CI 0.47-3.20). PGD 3 at 48- or 72-hours following pediatric lung transplantation was associated with shorter CLAD-free survival. Sex may be a modifier of this association.

22 May 2023 in Clinical Transplantation
Verified
Journal Article
Closed access
JEJonathan B. Edelson
Jonathan B. Edelson
XZXuemei Zhang
Xuemei Zhang
AGAndrew B. Goldstone
Andrew B. Goldstone
JRJoseph W. Rossano
Joseph W. Rossano
MOMatthew J. O'COnnor
Matthew J. O'COnnor
KMKatsuhide Maeda
Katsuhide Maeda

21 October 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
MCMichael A. Catalano
Michael A. Catalano
MSMax Shin
Max Shin
OTOmar Toubat
Omar Toubat
RRRadhika Rastogi
Radhika Rastogi
HBHalil Beqaj
Halil Beqaj
CMConstantine D. Mavroudis
Constantine D. Mavroudis
Background: Advances in procurement techniques have enabled use of hearts obtained via donation after circulatory death (DCD), expanding the donor pool; however, the impact of DCD heart transplant on outcomes in children is not well described. We aim to characterize waitlist survival and outcomes in pediatric heart transplant candidates listed for donation after brain death (DBD) versus DCD hearts. Methods: The United Network for Organ Sharing database was queried for patients aged <18 years at listing, waitlisted for heart transplant between January 2021 and June 2024. Patients were stratified by listing for DBD exclusively, versus DBD and DCD hearts. Waitlist and posttransplant outcomes were compared using Fine–Gray and Kaplan–Meier analyses. Results: Of 2449 listed patients, 2353 (96.1%) were listed for DBD hearts exclusively, and 96 (3.9%) for DCD hearts as well. DCD recipient candidates had increased rates of cardiopulmonary support and were more likely to be status 1A. Of DCD recipient candidates, 15 (15.6%) received DCD hearts and 50 (52.1%) received DBD hearts. When controlling for status, extracorporeal membrane oxygenation, blood type, region, and year, DCD listing was not associated with likelihood of transplant or waitlist death. Among status 1B/2 patients, DCD listing was associated with increased likelihood of transplant (adjusted subhazard ratio, 2.05 [95% CI, 1.16–3.62]; P =0.01). No patients in the status 1B/2 DCD subgroup died while waitlisted. There were no differences in 1‐year posttransplant survival. Conclusions: Among candidates for pediatric heart transplant listed as status 1B/2, patients listed for DCD hearts in addition to DBD hearts have shorter waitlist duration, improved transplant rates, lower waitlist mortality rates, and comparable survival to patients listed for DBD hearts alone.

22 September 2023 in JTCVS Techniques
Verified
Journal Article
Open access
GCGarrett N. Coyan
Garrett N. Coyan
MGMathew J. Gillespie
Mathew J. Gillespie
SEStanford G. Ewing
Stanford G. Ewing
KMKatsuhide Maeda
Katsuhide Maeda

3 February 2026 in Journal of the American Heart Association
Verified
Journal Article
Open access
CMCatherine M. Montgomery
Catherine M. Montgomery
RRRadhika Rastogi
Radhika Rastogi
ADAaron Dewitt
Aaron Dewitt
BKBenjamin W. Kozyak
Benjamin W. Kozyak
LHLynne Ha
Lynne Ha
JEJonathan B. Edelson
Jonathan B. Edelson
Background: In October 2022, our center implemented a standardized program to promote ventricular recovery in pediatric patients supported with durable ventricular assist devices. We report our experience and outcomes. Methods: The initiative consists of 4 core components for all patients with ventricular assist devices: (1) cultural shift: routine assessment for ventricular recovery for possible device explant or, in complex congenital heart disease (CHD), for further surgical palliation; (2) reverse remodeling—use of goal‐directed medical therapy as tolerated; (3) assessment of recovery: stepwise evaluation by echocardiography, exercise testing, and cardiac catheterization; and (4) multidisciplinary review of patients. This retrospective cohort study includes all patients who underwent durable ventricular assist device implantation between October 2022 and October 2024. Patient characteristics and outcomes are described for those explanted for recovery. Results: The cohort included 35 patients, 22 (63%) with Berlin Heart EXCOR and 13 (37%) with HeartMate 3. Indications included cardiomyopathy (60%, n=21), CHD (31%, n=11), coronary pathology (6%, n=2), and myocarditis (3%, n=1). Nine patients underwent explant (26% of all patients, 38% of patients without CHD). No patients with CHD met criteria for recovery. Median age of explanted patients was 1 year (interquartile range, 3 months–10 years), and all were discharged postexplant. Median follow‐up was 10 months (interquartile range, 5.5–20 months). One patient was relisted for transplant; the others remained outpatient with, at worst, mild ventricular dysfunction. Conclusions: A standardized approach to ventricular recovery was associated with explant in 26% of patients, exclusively among those without CHD. Short‐term postexplant outcomes are encouraging, supporting further study in larger cohorts.